Want an email alert every time a Finch Trade goes live? Sign up in your profile.

Nothing has changed since the Finch Trade yesterday – simply adding a few more shares to my core long-term position. This principal represents the remaining cash in my Health Savings Account that I no longer need after starting a new job. #unionsforthewin

The Trade

Relay Therapeutics is considered a Future Compounder position. I purchased 77.2 shares at $12.31 per share on May 19, 2026. The total transaction value was $950.

Outperformance Scenarios

Investing in individual stocks can be reduced to a simple question: "If I invest $1 in this individual stock at this price, will it outperform an equal passive investment in the S&P 500 at this level?" If you keep emotions and expectations in check, then you might be surprised to learn you don't need to swing for the fences.

Here's how shares of Relay Therapeutics will need to perform for the money invested in this Finch Trade to outperform passive investing in the S&P 500 in the next five years.

‍

Assumptions:

• The S&P 500 index gains 10% per year with dividends included – its historical average since 1990.
• S&P 500 closing level at time of purchase on May 19, 2026 = 7,365
• Relay Therapeutics purchase price on May 19, 2026 = $12.31 per share

Margin of Safety & Allocation

Relay Therapeutics is considered a Future Compounder position. The estimated fair valuation based on my current model is below:

• Market close May 19: $12.07 per share
• Modeled Fair Valuation: $17.68 per share

Relay Therapeutics reported 178.725 million shares outstanding as of February 20, 2026. The modeled fair valuation above assumes 237.5 million shares outstanding, which represents dilution expected through the initial launch of zovegalisib.

Further Reading

• May 19, 2026 real-time announcement on Discord